Mechanisms and models in heart failure: A combinatorial approach

Circulation

Volumn 100, Issue 9, 1999, Pages 999-1008

  Mann, Douglas L ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytokine; Heart failure; Mechanism remodeling; Neurohormone

Indexed keywords

HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FUNCTION; HEART OUTPUT; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0033621141     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.9.999     Document Type: Review

References (78)

1. Packer M. How should physicians view heart failure? - The philosophical and physiological evolution of three conceptual models of the disease. Am J Cordiol. 1993;71:C3-C11.
2. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254.
3. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBiano R, Zeldis SM, Hendrix GH, Bommer WJ, Ulkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325: 1468-1475.
4. Massie BM. 15 years of heart-failure trials: what have we learned? Lancet. 1998;352(suppl 1):29-33.
5. Konstam MA, Dracup K, Baker DW, Bottorff MB, Brooks N, Dacey RA, Dunbar SB, Jackson AB, Jessup M, Johnson JC, Jones RH, Luchi RL, Massie BM, Pitt B, Rose EA, Rubin EA, Wright RF, Hadorn DC. Clinical Practice Guideline Number 11: Heart Failure: Evaluation and Care of Patients With Left-Ventricular Systolic Dysfunction. Rockville, MD: US Department of Health and Human Services; 1994. AHCPR Publication 94-0612.
6. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, Kopin IJ, Goldstein DS, Esler MD. Cardiac sympathetic nerve function in congestive heart failure. Circulation. 1996;93:1677-1676.
7. Eichhorn EJ, Bristow M. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation. 1997;94:2285-2296.
8. Hasking GJ, Esler MD, Jennings GL, Burton D, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615-621.
9. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure: relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med. 1984;310: 347-352.
10. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981;63:645-651.
11. Bristow MR. The adrenergic nervous system in heart failure. N Engl J Med. 1984;311:850-851.
12. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ Res. 1991;69:1185-1195.
13. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85: 790-804.
14. Bozkurt B, Kribbs S, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL. Pathophysiologically relevant concentrations of tumor necrosis factor-a promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97: 1382-1391.
15. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman B, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes V, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325: 303-310.
16. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
17. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med. 1992;327:685-691.
18. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807-2816.
19. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler M, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1350-1355.
20. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, Mckillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group [see comments]. N Engl J Med. 1995;333: 1301-1307.
21. Wolny A, Clozel J-P, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997;80:219-227.
22. Hoit BD, Shao Y, Kinoshita A, Gabel M, Husain A, Walsh RA. Effects of angiotensin II generated by an angiotensin converting enzymeindependent pathway on left ventricular performance in the conscious baboon. J Clin Invest. 1995;95:1519-1527.
23. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation. 1995;91:2504-2507.
24. Douglas PS, Morrow R, Ioli A, Reicheck N. Left ventricular shape, afterload, and survival in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1989;13:311-315.
25. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med. 1997;336:1350-1355.
26. Linzbach AJ. Heart failure from the point of view of quantitative anatomy. Am J Cardiol. 1960;69:370-382.
27. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohimeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, Bristow MR. Changes in gene expression in the intact human heart. Downregulation of a-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest. 1997;100: 2315-2324.
28. Schaper J, Froede R, Hein ST, Buck A, Hashizume H, Speiser B, Friedl A, Bleese N. Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation. 1991;83: 504-514.
29. Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation. 1992;85:1046-1055.
30. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and b-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205-211.
31. Davies CH, Davia K, Bennett JG, Pepper JR, Poole-Wilson PA, Harding SE. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation. 1995;92: 2540-2549.
32. Tsutsui H, Spinale FG, Nagatsu M, Schmid PG, Ishihara K, DeFreyte G, Cooper G IV, Carabello BA. Effects of chronic b-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest. 1994;93:2639-2648.
33. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154-1161.
34. Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation. 1998;97:2316-2322.
35. Josue O. Hypertrophie cardioque caus'ee par l'adrenaline et la toxine typhique. C R Soc Biol (Paris). 1907;63:285-290.
36. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation. 1997;96:2953-2958.
37. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, Khaw B-A. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 1996;335:1182-1189.
38. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC, Anversa P. Apoptosis in the failing human heart. N Engl J Med. 1997;336:1131-1141.
39. Cheng W, Li B, Kajstura J, Li P, Wolin MS, Sonnenblick EH, Hintze TH, Olivetti G, Anversa P. Stretch-induced programmed myocyte cell death. J Clin Invest. 1995;96:2247-2259.
40. Leri A, Claudio PP, Li Q, Wang X, Reiss K, Wang S, Malhotra A, Kajstura J, Anversa P. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activatiing p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to Bax protein ratio in the cell. J Clin Invest. 1998;101:1326-1342.
41. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, Glembotski CC, Quintana PJE, Sabbadini RA. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98: 2854-2865.
42. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the b-adrenergic pathway. Circulation. 1998;98:1329-1334.
43. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley JA III, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage heart failure. Circulation. 1998;97:1708-1715.
44. Tyagi SC, Kumar S, Voelker DJ, Reddy HK, Janicki JS, Curtis JJ. Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem. 1996;63:185-198.
45. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem. 1996;155: 13-21.
46. Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation. 1998;98:1728-1734.
47. Weber KT. Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation. Circulation. 1997;96:4065-4082.
48. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis - functional significance and regulatory factors. Cardiovasc Res. 1993;27:341-348.
49. Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension. 1994;23:869-877.
50. Nakatani S, McCarthy PM, Kottke-Marchant K, Harasaki H, James KB, Savage RM, Thomas JD. Left ventricular echocardiographic and histologic changes: impact of chronic unloading by an implantable ventricular assist device. J Am Coll Cardiol. 1996;27:894-901.
51. Krayenbuehl HP, Hess OM, Schneider J, Turina M. Left ventricular function and myocardial structure in aortic valve disease before and after surgery. Herz. 1984;9:270-278.
52. Villari B, Campbell SE, Hess OM, Mall G, Vassalli G, Weber KT, Krayenbuehl HP. Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. J Am Coll Cardiol. 1993;22:1477-1484.
53. Ross J Jr. Afterload mismatch in aortic and mitral valve disease: implications for surgical therapy. J Am Coll Cardiol. 1985;5:811-826.
54. Ross JJ. Mechanisms of cardiac contraction. What roles for preload, afterload and inotropic state in heart failure? Eur Heart J. 1983;4(suppl A): 19-28.
55. Hirota Y, Saito T, Kita Y, Shimizu G, Kino M, Kawamura K. The natural history of dilated cardiomyopathy and pathophysiology of congestive heart failure. J Cardiogr (suppl) 1986;67-76.
56. Pouleur H, Rousseau MF, van Eyll C, Melin J, Youngblood M, Yusuf S. Cardiac mechanics during development of heart failure. SOLVD Investigators. Circulation. 1993;87:IV14-IV20.
57. Vatner SF. Reduced subendocardial myocardial perfusion as one mechanism for congestive heart failure. Am J Cardiol. 1988;62:94E-98E.
58. Shannon RP, Komamura K, Shen YT, Bishop SP, Vatner SF. Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart failure. Am J Physiol. 1993;265:H801-H809.
59. LeGrice IJ, Takayama Y, Holmes JW, Covell JW. Impaired subendocardial function in tachycardia-induced cardiac failure. Am J Physiol. 1995;268:H1788-H1794.
60. Givertz MM, Colucci WS. New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet. 1998; 352(suppl 1):SI34-SI38.
61. Kapadia S, Oral H, Lee J, Nakano M, Taffet GE, Mann DL. Hemodynamic regulation of tumor necrosis factor-α gene and protein expression in adult feline myocardium. Circ Res. 1997;81:187-195.
62. Sadoshima JI, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993;75:977-984.
63. Kono T, Sabbah HN, Rosman H, Alam M, Jafri S, Goldstein S. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol. 1992;20:1594-1598.
64. McCarthy PM, Nakatani S, Vargo R, Kottke-Marchant K, Harasaki H, James KB, Savage RM, Thomas JD. Structural and left ventricular histologic changes after implantable LVAD insertion. Ann Thorac Surg. 1995;59:609-613.
65. Levin HR, Oz MC, Chen JM, Packer M, Rose EA, Burkhoff D. Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. Circulation. 1995;91:2717-2720.
66. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict CR, Shelton B. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Circulation. 1995;91:2573-2581.
67. Sutton MSJ, Pfeffer MA, Plappert T, Rouleau J-L. Moye LA, Dagenais GR, Lamar GA, Klein M, Sussex B, Goldman S, Menapace FJ Jr, Parker JO, Lewis S, Sestier F, Gordon DF, McEwan P, Bernstein V, Braunwald E. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation. 1994;89: 68-75.
68. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol. 1998;29: 1060-1066.
69. Colucci WS. Apoptosis in the heart. N Engl J Med. 1996;335:1224-1226.
70. Givertz MM, Colucci WS. New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet. 1998;352: 34-38.
71. Koh GY, Klug MG, Soonpaa MH, Field LJ. Differentiation and long-term survival of C2C12 myoblast grafts in heart. J Clin Invest. 1993; 1548-1554.
72. Schneider MD. Myocardial infarction as a problem of growth control: cell cycle therapy for cardiac myocytes? J Card Fail. 1996;2:259-263.
73. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, Pardo F, Biondi B, Sacca L. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 1996;334:809-814.
74. Mann DL, Spinale FG. Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation. 1998;98: 1699-1702.
75. CIBIS Investigators, and Committee. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomized trial. Lancet. 1999;353:9-13.
76. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PJ, for the ELITE Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study. ELITE). Lancet. 1997;349:747-752.
77. Koch WJ, Rockman HA, Samama P, Hamilton R, Bond RA, Milano CA, Lefkowitz RJ. Cardiac function in mice overexpressing the b-adrenergic receptor kinase or a bARK inhibitor. Science. 1995;268:1350-1353.
78. Akhter SA, Skaer CA, Kypson AP, McDonald PH. Peppel KC, Glower DD, Lefkowitz RJ, Koch WJ. Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci USA. 1998;94:12100-12105.